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SUMMARY – In recent years, there has been increased interest in the cost of treatment for revi-
sion interventions for hip and knee prostheses. In all publications so far, the authors note the high cost 
of treatment for revision interventions, especially if infection is present. The aim of this study was to 
compare the cost of treatment and health insurance reimbursements between revision total hip arthro-
plasty (THA) for infection and revision for aseptic indications (aseptic instability and periprosthetic 
fracture). Hospital data on 168 patients having undergone revision THA between 2010 and 2018 at 
the Department of Traumatology, Sestre milosrdnice University Hospital Centre from Zagreb were 
analyzed. Financial data were collected from the Hospital Information System. Financial analysis 
included total cost per patient, Croatian Health Insurance Fund reimbursements, cost of implants, and 
length of hospital stay. The difference between the mean total cost per patient and the mean Croatian 
Health Insurance Fund reimbursements was -262.83 € (-6.08%) for aseptic instability, -1694.94 € 
(-17.25%) for infection and -916.49 € (-17.33%) for periprosthetic fracture. The Croatian Health 
Insurance Fund does not recognize differences in the cost of revision THA for aseptic instability, in-
fection and periprosthetic fracture. Health insurance reimbursement is inadequate for centers that 
offer revision hip surgery.
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Introduction
The most common reasons for revision total joint 
arthroplasty published in the literature are instability 
with or without aseptic loosening, infection and 
periprosthetic fracture1-3. In recent years, due to the 
high cost of treatment for revision prosthetic surgery, 
there has been increased interest in this issue4-7, 
especially as health insurance institutions are not 
considered to cover treatment costs8. In Croatia, the 
cost of treatment for revision surgery of hip prosthesis 
has not been analyzed so far, which also holds for 
payment of the Croatian health insurance for revision 
hip surgery, including aseptic or septic instability, 
which needs revision after total hip prostheses and/or 
periprosthetic hip fractures.
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Methods
We analyzed hospital data on 168 patients having 
undergone revision total hip arthroplasty (THA) 
between 2010 and 2018 at the Department of 
Traumatology, Sestre milosrdnice University Hospital 
Centre from Zagreb. Financial data were collected 
from the Hospital Information System. Financial 
analysis included total cost per patient, Croatian Health 
Insurance Fund reimbursements, cost of implants, and 
length of hospital stay. Patients were divided into three 
groups according to indications for revision THA, as 
follows: aseptic instability, infection and periprosthetic 
fracture (which requires treatment with some kind of 
revision type of hip prosthesis). On statistical analysis, 
Student’s t-test at 95% confidence level (p<0.05) was 
used. The cost of treatment, reimbursement and cost of 
implants were expressed in €.
Results
During the 2010-2018 period, 168 patients 
underwent revision THA. Their mean age was 70.82 
(range 47-92, SD 9.73) years. There were 73 (43.5%) 
male and 95 (56.5%) female patients. Indications for 
surgery were aseptic loosening and instability in 89 
(52.9%), infection in 35 (20.8%) and periprosthetic 
fracture in 44 (26.1%) cases (Fig. 1).
periprosthetic fracture is shown in Table 2. The cost of 
implants for aseptic loosening and instability, infection 
and periprosthetic fracture is shown in Table 3. The 
mean total cost was significantly higher for those 
undergoing revision for infection (9825.47 €; SD 
5913.29) than in the aseptic loosening and instability 
group (4324.86 €; SD 1266.25; p<0.001, unpaired 
t-test). The mean total cost was significantly higher for 
those undergoing revision for infection (9825.47 €; 
Fig. 1. Distribution of indications for revision 
total hip arthroplasty.
Table 1. Total cost of treatment for aseptic loosening  























Table 2. Health insurance reimbursements for aseptic 


























Total cost of treatment for aseptic loosening and 
instability, infection and periprosthetic fracture is 
shown in Table 1. Health insurance reimbursements 
for aseptic loosening and instability, infection and 
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SD 5913.29) than in the periprosthetic fracture group 
(5289.25 €; SD 1836.67; p<0.004, unpaired t-test). 
The mean total cost was significantly higher for those 
undergoing revision for periprosthetic fracture 
(5289.25 €; SD 1836.67) than in the aseptic loosening 
and instability group (4324.86 €; SD 1266.25; p<0.013, 
unpaired t-test). The length of hospital stay (in days) 
for aseptic loosening and instability, infection and 
periprosthetic fracture is shown in Table 4. Financial 
analysis of revision hip arthroplasty for aseptic 
loosening and instability, infection and periprosthetic 
fracture is shown in Table 5.
Discussion
In the USA, an estimated 2.5 million people are 
living with hip replacement9. Revision THA is a 
complex procedure that is associated with a greater risk 
for patients and greater cost for the treating hospital 
when compared with primary THA. Revised procedures 
for periprosthetic joint infection (PJI) are associated 
with a significantly higher number of hospitalizations, 
hospital days and number of operations, as well as longer 
operating time, more blood loss, prolonged antibiotic 
therapy, higher number of radiographic examinations, 
and more total outpatient visits during 12-month period 
following the index procedure. Complications will 
become an accruing burden to the health care system in 
the next two decades10-13. The economic impact of PJI is 
significant. The overall cost to the American health care 
system to treat PJI was 566 million dollars in 2009, a 
number that is projected to reach 1.62 billion dollars in 
202014.
In some national health insurance systems, in-
stitutions do not recognize this problem. For example, a 
study undertaken in Germany8 found that reim-
bursement was inadequate. In this study, a total of 281 
patients were treated in 2015 due to infection of the 
Table 3. Cost of implants for aseptic loosening  
























Table 4. Length of hospital stay for aseptic loosening  


























Table 5. Financial analysis of revision hip arthroplasty for aseptic loosening and instability,  
infection and periprosthetic fracture
Mean total cost (€) Mean health insurance reimbursement (€) Deficit (€)
Aseptic loosening and instability 4324.86 4062.03 -262.83 (-6.08%)
Infection 9825.47 8130.53 -1694.94 (-17.25%)
Periprosthetic fracture 5289.25 4372.76 -916.49 (-17.33%)
S. Sabalić et al. The CHIF does not recognize differences in the cost for revision THA
670 Acta Clin Croat, Vol. 59, No. 4, 2020
musculoskeletal system. Of these, 144 patients had 
periprosthetic infection of the knee or hip joint. Total 
cost of these 281 treatments was 3.3 million € but only 
2.7 million were covered by the diagnosis-related groups 
(DRG) revenues (underpaid by approximately 20%). 
This corresponded to a deficit of 633,000 €, with a mean 
deficit per treatment case of 2300 €. The deficit for 
infected THA was about 8500 € on average and was five 
times greater than for infected total knee arthroplasty 
(TKA) with ⁓1600 €. The main reasons for the high 
treatment costs were the length of hospital stay, multiple 
surgical interventions, and isolation treatment8.
In our study, we aimed to evaluate the economic 
burden of the cost of revision THAs and health 
insurance reimbursements, with special emphasis on 
the cost of treating patients with revision THA for 
PJIs at a university hospital in a middle-income EU 
country. We found that the mean total cost was 
significantly higher for those undergoing revision for 
infection as compared with the aseptic loosening and 
instability group (p<0.001) and the periprosthetic 
fracture group (p<0.004). In addition, the mean total 
cost was significantly higher for those undergoing 
revision for periprosthetic fracture than in the aseptic 
loosening and instability group (p<0.013).
Also, the mean cost of implants was about 1800 € 
for aseptic loosening and instability, 2300 € for 
infection and 1700 € for fracture. The mean length of 
hospital stay (in days) was 20, 64 and 26 days for 
aseptic loosening and instability, infection and fracture, 
respectively. All hospitalizations and rehospitalizations 
were included in the study.
We compared the mean total cost and the mean 
Croatian Health Insurance Fund reimbursements and 
found the mean deficit of 260 € for aseptic loosening 
and instability, 1700 € for infections, and 900 € for 
periprosthetic fracture. Patients with PJI require 
repetitive hospitalization, more days of hospitalization, 
more surgical procedures and antibiotic therapy, which 
increases the cost of treatment as opposed to revision 
for aseptic instability or periprosthetic fracture. The 
Croatian Health Insurance Fund reimburses the same 
amount through the DRG system for different 
indications and treatment modalities in revision hip 
surgery and therefore the highest deficit is generated 
in the case of infection.
Kallala et al.15 examined inpatient hospital data on 
168 revision TKAs. They found that revision surgery 
for infection was associated with a mean length of stay 
more than double that in aseptic cases. The mean cost 
of revision for infection was more than three times 
that of aseptic revision. Total reimbursement was 1.9 
million £, yielding an average loss of 4.5 thousand £ 
per case in 168 cases15.
Our study had several limitations. These were 
retrospective design and data on the costs were 
obtained using the hospital accounting system. 
Therefore, we could not obtain and differentiate (other 
costs) all cost data for economic analyses. We can 
expect that the overall cost of treatment is much 
higher, especially in case of infection and if the patient 
is active because these is only the cost of treatment at 
the hospital, without the cost of treatment outside 
hospitals, as well as the possible loss of income for the 
patient.
Croatia is a country with a significant share of 
public social health and small share of private sector. 
The cost of treatment in hospitals is arbitrary and is 
determined by the Croatian Health Insurance 
Directorate. So far, hospital institutions have not 
commented on the cost of treatment for revision 
interventions after THA and reimbursements from 
the Croatian Health Insurance Fund.
In the Croatian health system, we do not have a 
system where patients with these conditions are 
transferred to centers of excellence, to reduce treatment 
costs8. There is no broader social understanding of the 
length and cost of treating hip revision interventions, 
especially for infection. Organized education of all 
medical professionals on the prevention of surgical 
infections should be introduced in the Croatian health 
system, as well as raising awareness of the cost of 
treating bone infections.
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Sažetak
HRVATSKI FOND ZA ZDRAVSTVENO OSIGURANJE NE PREPOZNAJE RAZLIKE  
U TROŠKOVIMA RAZLIČITIH MODALITETA REVIZIJE TOTALNE ARTROPLASTIKE KUKA
S. Sabalić, D. Vidović, S. Babić, T. Ćuti, D. Gajski, K. Rotim i D. Blažević
Posljednjih godina sve je veći interes za troškove liječenja revizijskih intervencija kod endoproteza kuka i koljena. U svim 
dosadašnjim publikacijama autori bilježe visoke troškove liječenja revizijskih intervencija, osobito ako je prisutna infekcija. 
Cilj ove studije bio je usporediti troškove liječenja i naknade zdravstvenog osiguranja između revizije totalne artroplastike 
kuka za infekciju i revizije za aseptične indikacije (aseptična nestabilnost i periprotetski prijelom). Analizirani su bolnički 
podaci 168 bolesnika koji su bili podvrgnuti reviziji totalne artroplastike kuka u razdoblju od 2010. do 2018. godine na Kli-
nici za traumatologiju Kliničkog bolničkog centra Sestre milosrdnice u Zagrebu. Financijski podaci prikupljeni su iz bolnič-
kog informacijskog sustava. Financijska analiza uključivala je ukupni trošak po bolesniku, troškove hrvatskog zdravstvenog 
osiguranja, troškove implantata i duljinu boravka u bolnici. Razlika između srednje vrijednosti ukupnog troška po bolesniku 
i srednje vrijednosti povrata hrvatskog zdravstvenog osiguranja bila je -262,83 € (-6,08%) za aseptičnu nestabilnost, -1694,94 
€ (-17,25%) za infekciju i -916,49 € (-17,33%) za periprotetski prijelom. Hrvatski fond za zdravstveno osiguranje ne prepo-
znaje razlike u troškovima revizije totalne endoproteze kuka za aseptičnu nestabilnost, infekciju i periprotetski prijelom. 
Naknada za zdravstveno osiguranje nije odgovarajuća za centre koji obavljaju reviziju kuka.
Ključne riječi: Revizija totalne artroplastike kuka; Infekcija; Periprotetski prijelom; Aseptična nestabilnost; Financijska analiza
